Stocks in Play - December 8th 2025

Stocks in Play: Biotech Bonanza

Welcome to today's Stocks in Play report. Below are the key stocks to watch, along with brief x-ray and analysis.

If you find this Newsletter helpful and ever want to say thank you then feel free to Buy Me a Coffee. It’ll inspire me to work faster….

Yesterday In Review

Reviewing Friday quickly here. I took RBRK on the $85 Undercut and Rally (My favoured entry), ULTA on the 1 minute ORB and PRAX on the 1 minute ORB. I cut PRAX toward the end of the day as it was closing near the lows. I took a trim on WMT position and KEYS. DG turned out to be a poor miss passing on it on Thursday. I should have absolutely taken the $115 U&R.

Market Awareness

Bullish overall. Not much to say. Concentrating on individual names, aware of upcoming Earnings and Macro catalysts and just proceeding with normal routine until something changes. All indicators are green.

It seems to be mostly biotechs I’m looking at recently. This is not by design it’s just what is catching my eye.

Today’s Picks

OCUL: Ocular Therapeutix announced an accelerated regulatory pathway for AXPAXLI in wet AMD, now planning to submit an NDA following 1-year data from SOL-1 (Q1 2026) rather than waiting for 2-year data or a second Phase 3 trial. Not entirely sure about catalyst here but the chart is really nice so I’m willing to trade it. Note that Data is due in Q1 2026. This isn't new clinical data - it's a timeline acceleration based on evolving FDA guidance and the company's confidence in their trial design.

X-Ray OCUL: Industry Group: Biotechnology, Market Cap: 2.68B, Float: 186.81M Short Interest 7.05%, Days to Cover: 4.66, Exchange: NASDAQ

WVE: Wave announced positive interim data from the INLIGHT Phase 1 trial evaluating WVE-007, a GalNAc-siRNA targeting INHBE for obesity treatment. In the 240mg single-dose cohort (n=32, BMI ~32), WVE-007 demonstrated 9.4% visceral fat reduction (p=0.02), 4.5% total fat reduction (3.5 lbs, p=0.07), and 3.2% lean mass increase (4.0 lbs, p=0.01) at 3 months versus baseline.

My understanding here is that the bull case is that this treatment causes much less muscle loss which is a gripe of GLP-1s. Hence the move. Chart is okay. Coming into resistance here now but could continue to run. High Short interest.

Note GPCR have also come out with GLP-1 Data today which is interesting that both would be out the same day. WVE seems somewhat promotional so I think it will be a short term move.

X-Ray WVE: Industry Group: Biotechnology, Market Cap: 1.25B, Float: 134.97M Short Interest 11.42%, Days to Cover: 5.96, Exchange: NASDAQ

X-Ray GPCR: Industry Group: Biotechnology, Market Cap: 2.10B, Float: 59.31M Short Interest 8.91%, Days to Cover: 5.04, Exchange: NASDAQ

Other Biotechs moving hard are IBIO & FULC. I’m watching them all today. These are coinciding with presentations at the ASH Conference over the weekend.

WVE, GPCR, OCUL, FULC, IBIO

Delayed Reaction Watchlist (click here Tradingview)

Sources & Services I Use in my Trading:

• Finviz - Short Interest, Float, Articles, Fundamentals (Free)

• Benzinga Pro - News Source + News Squawk + Earnings Data (Paid)

• Tradingview - Charting & Scanning (Paid)

• Koyfin - Fundamental Data (Paid)

• EarningsWhispers - Earnings Calendar (Free)

• Tradersync - Trade Journal (Paid)

_{PS: There are many ways to trade stocks in play. It does not have to be the one that keeps going straight up and sometimes it doesn’t even have to be day one of the catalyst. Everyone must find a setup, timeframe and method that works for them. This list is supposed to educate on the criteria I use and the methods in which I find Stocks in Play. Yours may differ and that is completely okay.}